Refine Search
(10)
(10)
(10)
(10)

Central Nervous System

The CNS therapeutics market is collectively one of the fastest growing markets within the pharmaceutical industry. The primary factors driving the global CNS therapeutics market include the increasing ageing population and the substantial gap in unmet clinical need for major CNS disorders. This unmet gap can be assessed from the fact that not a single novel drug has been approved for Alzheimer’s disease in over 10 years.

Spinal Cord Injury - Pipeline Review, H1 2018

  • $2,000
  • April 2018
Add to Basket Quick View Add to Saved List

Global Markets Direct’s, ‘Spinal Cord Injury - Pipeline Review, H1 2018’, provides an overview of the Spinal Cord Injury pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Spinal C...

Schizophrenia - Pipeline Review, H1 2018

  • $2,000
  • April 2018
Add to Basket Quick View Add to Saved List

Global Markets Direct’s, ‘Schizophrenia - Pipeline Review, H1 2018’, provides an overview of the Schizophrenia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Schizophrenia, com...

Cancer Pain - Pipeline Review, H1 2018

  • $2,000
  • April 2018
Add to Basket Quick View Add to Saved List

Global Markets Direct’s, ‘Cancer Pain - Pipeline Review, H1 2018’, provides an overview of the Cancer Pain pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Cancer Pain, complete ...

Insomnia - Pipeline Review, H1 2018

  • $2,000
  • April 2018
Add to Basket Quick View Add to Saved List

Global Markets Direct’s, ‘Insomnia - Pipeline Review, H1 2018’, provides an overview of the Insomnia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Insomnia, complete with anal...

Migraine - Pipeline Review, H1 2018

  • $2,000
  • April 2018
Add to Basket Quick View Add to Saved List

Global Markets Direct’s, ‘Migraine - Pipeline Review, H1 2018’, provides an overview of the Migraine pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Migraine, complete with anal...

Opium (Opioid) Addiction - Pipeline Review, H1 2018

  • $2,000
  • March 2018
Add to Basket Quick View Add to Saved List

Global Markets Direct’s, ‘Opium (Opioid) Addiction - Pipeline Review, H1 2018’, provides an overview of the Opium (Opioid) Addiction pipeline landscape.

The report provides comprehensive information on the therapeutics under development ...

Depression - Pipeline Review, H1 2018

  • $2,000
  • March 2018
Add to Basket Quick View Add to Saved List

Global Markets Direct’s, ‘Depression - Pipeline Review, H1 2018’, provides an overview of the Depression pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Depression, complete wit...

Alzheimer's Disease - Pipeline Review, H1 2018

  • $2,500
  • February 2018
Add to Basket Quick View Add to Saved List

Global Markets Direct’s, ‘Alzheimer's Disease - Pipeline Review, H1 2018’, provides an overview of the Alzheimer's Disease pipeline landscape.

The report provides comprehensive information on the therapeutics under development fo...

Epilepsy - Pipeline Review, H1 2018

  • $2,000
  • February 2018
Add to Basket Quick View Add to Saved List

Global Markets Direct’s, ‘Epilepsy - Pipeline Review, H1 2018’, provides an overview of the Epilepsy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Epilepsy, complete with anal...

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H1 2018

  • $2,000
  • February 2018
Add to Basket Quick View Add to Saved List

Global Markets Direct’s, ‘Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H1 2018’, provides an overview of the Attention Deficit Hyperactivity Disorder (ADHD) pipeline landscape.

The report provides comprehensive info...